Business
BillionToOne Announces Selection of Northstar Select® as the new liquid biopsy test for LC-SCRUM-TRY clinical study at National Cancer Center Hospital East
BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the selection of Northstar Select® as the new liquid biopsy in LC-SCRUM-TRY- Japan, a nationwide, multi-center study to better elucidate the mechanisms of drug resistance and the characteristics of drug-resistant lung cancer. Launched by the National Cancer Center Hospital East (Kashiwa, Japan; "NCCHE") in 2020 with ov
About this update from Billiontoone, Inc.
[{"type":"text","content":"Ultra-sensitive liquid biopsy is expanding precision medicine access for patients in Japan with treatment-resistant non-small cell lung cancer (NSCLC)","length":150,"tagName":"p","attribs":{}},{"type":"text","content":"MENLO PARK, Calif., Jan. 6, 2026 /PRNewswire/ -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the selection of Northstar Select® as the new liquid biopsy in LC-SCRUM-TRY- Japan, a nationwide, multi-center study to better elucidate the mechanisms of drug resistance and the characteristics of drug-resistant lung cancer. Launched by the National Cancer Center Hospital East (Kashiwa, Japan; "NCCHE") in 2020 with over 100 institutions as part of its network, the study analyzed approximately 2,000 clinical specimens from patients with advanced or recurrent non-small cell lung cancer (NSCLC) following drug resistance, with genomic analysis primarily performed using tissue biopsies from drug-resistant tumors.","length":855,"tagName":"p"},{"type":"image","alt":"BillionToOne logo (PRNewsfoto/BillionToOne)","displaySize":"","headline":null,"caption":"BillionToOne logo (PRNewsfoto/BillionToOne)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":121,"url":"https://media.zenfs.com/en/prnewswire.com/20c9d4f2a4e11a8715e2cb466cbe9442"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/KXnIRmSRXCDdDYiP3GJB2g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIxMztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/20c9d4f2a4e11a8715e2cb466cbe9442","width":400,"height":121}},"href":"https://mma.prnewswire.com/media/1855547/Billion_To_One_Logo_New.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Obtaining biopsy samples for tissue-based genomic analysis from drug-resistant tumors is often challenging in NSCLC due to reasons such as difficult to biopsy tumor locations, insufficient tumor sample, and patient reluctance to undergo invasive procedures. To overcome these barriers, the investigators adopted plasma-based liquid biopsy using cell-free DNA (cfDNA) genomic analysis as a non-invasive alternative to tissue-based genomic testing.","length":446,"tagName":"p"},{"type":"text","content":"With sensitivity as a critical performance metric, investigator...